Its R&D capabilities span small molecules, cell therapies, and gene editing, with a robust portfolio extending from discovery to Phase IV programs.

In Jan 2024, Galapagos announced its intent to separate into two publicly traded entities: one focused on its innovative drug pipeline and the other on its mature product portfolio.

Galapagos will focus on unlocking the broad-reaching potential of its decentralized cell therapy manufacturing platform in oncology and will continue to advance its cell therapy pipeline. Galapagos’ lead CAR-T candidate, GLPG5101, has demonstrated an encouraging efficacy and safety profile in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL), supporting the feasibility of Galapagos’ innovative decentralized cell therapy manufacturing platform in delivering fresh, fit cells with a vein-to-vein time of seven days.